Anebulo Pharmaceuticals, Inc. announced the appointment of Sandra Gardiner as the company's acting chief financial officer. Ms. Gardiner joins the company from Pulse Biosciences, Inc., where she served as chief financial officer until December 2022. She brings over 30 years of financial, operational and management experience, with demonstrated leadership and a strong network within the investor and financial analyst community.

Ms. Gardiner succeeds Rex Merchant, who served as the company's chief financial officer since its inception and helped guide the company through a successful IPO in May 2021.